Dataset from Multicenter, Randomized, Open-Label, Efficacy Assessor-Blinded, Active Comparator-Controlled Phase 3b Study to Compare the Efficacy of Guselkumab to Fumaric Acid Esters (Fumaderm Initial/ Fumaderm) for Adult Patients With Moderate to Severe Plaque Psoriasis Who Are Candidates for and Naive to Systemic Treatment

The purpose of the study is to compare the efficacy of Guselkumab with commercially available
active comparator Fumaderm initial/Fumaderm tablets for the treatment of adult participants
with moderate to severe plaque-type psoriasis who have not yet received any systemic therapy.